I really don't want to be a doctor

Chapter 121 Jing Xiaoran's Conditions (Part [-])

"Mr. Jing, what do you think?" Hammer said softly.

Aside from other things, it would not be an exaggeration to call him a genius, or even a monster, to develop a new drug at such a young age.

If this kind of person can enter Pfizer, it will definitely make a lot of money for Pfizer.

Jing Xiaoran gently placed the contract on the table and looked at Hamer with a playful look in his eyes.

Pfizer's senior engineer?Or is it the lead engineer?
Others may think that this condition is very good. If you join Pfizer, you will have no worries about food and clothing, fame and fortune for the rest of your life.

But Jing Xiaoran knew that once he became an engineer of Pfizer, it meant that all his research results would be attributed to Pfizer from now on, including this new oral anticoagulant.

Everything developed by Xiao Ran in the future will be labeled as Pfizer.

Don't look at Pfizer as a massive bloodletting, but actually set a trap for Jing Xiaoran to sneak into it.

"Mr. Hammer, is this your greatest sincerity?" Jing Xiaoran stared at Hammer closely, "Maybe I should wait for AstraZeneca or Bayer's pharmaceutical representatives to see what conditions they offer."

Hammer's smile froze on his face, and his hands froze.

Indeed, these conditions sound like hype, but they are actually some of the most basic conditions for Pfizer to buy out patents.

Hammer originally thought that Jing Xiaoran was highly regarded, but he didn't expect that he looked like a freshman, but an old fritter who was familiar with the medical circle.

Unexpectedly, he was unmoved by such generous conditions.

"Mr. Jing, we can increase the buyout fund to 1000 million US dollars, and other conditions remain unchanged." Hammer paused and said, "What do you think?"

"Ha ha."

Jing Xiaoran leaned back on the sofa, with a smile on his lips, and slowly said: "Hammer, as far as I remember, Pfizer bought a drug patent from the Lawrence Berkeley National Laboratory in the United States last year and spent 8 million US dollars. "

"Do you think the conditions you offered are worth 8 million US dollars?"

"Or, do you think the new oral anticoagulant is not worth the $8 million buyout fee?"

Hammer was taken aback for a moment, he didn't expect Jing Xiaoran to really understand the market of the medical industry so well.

A buyout fee of US$8 million is commonplace in the medical field, and even a buyout fee of more than one billion US dollars is commonplace.

but……

Those are bought from large laboratories around the world!
For example, Lawrence Berkeley National Laboratory, the most famous laboratory in the United States, has developed many new drugs from this experiment, but the research and development costs are huge.

The buyout fee of 8 million US dollars seems to be a lot of money, but excluding the research and development funds, the remuneration that can be left to all members of the laboratory is actually not much.

As for this new type of oral anticoagulant, at present, Jing Xiaoran is the only research and development member. As for Jing Xiaoran's research and development funds...

Hammer guessed that it might not exceed [-] Huaxia coins.

Let them Pfizer pay 8 million US dollars to buy out such a patent...

In all fairness, Pfizer is reluctant and will not pay so much.

If it was a big laboratory, they would definitely give the money right away without saying a word, not to mention 8 million US dollars, more than a billion US dollars would do!
"Mr. Jing, you can't say that." Hammer mused, "On a larger scale, what we at Pfizer are buying is a patent for a new drug. On a smaller scale, what we are buying is just a chemical formula, a Synthetic process of pharmaceuticals."

"Now it's just a compound. We can't get some compound and just pour it into our mouths."

Formulation development is an important part of drug application.

For example, some drugs are poorly absorbed by the gastrointestinal tract, so they need to be developed into injections.Some drugs will lose their activity in gastric acid, so they need to be developed into enteric-coated preparations.Some compounds have poor solubility, which can also be partially solved by formulation.

Hammer continued: "Even when a compound has passed preclinical testing, we have to submit an investigational new drug application to the FDA (US Food and Drug Administration) so that the compound can be used in human trials."

"Once drug candidates pass initial testing, the real challenge begins for them. They have to show in clinical trials that they are effective and well tolerated."

"Before it goes on the market, it needs to go through phase 1, 2, and 3 clinical trials. Even after it goes on the market, the drug is still under the supervision of experts. This is the phase 4 clinical trial. All side effects observed in patients taking the drug must be reviewed. Write it down and list it in the instruction manual."

"If a drug approved for marketing is discovered at this stage with serious adverse reactions that were not found in previous studies, such as a significant increase in the incidence of cardiovascular disease in the population taking the drug, the drug will also be forcibly removed from the shelves by the regulatory authorities."

"Some drugs have only been on the market for a year, and they were forced to withdraw from the shelves due to poor phase 4 clinical evaluation."

Hammer's words were very sincere, and it was quite laborious to speak in his squishy Chinese language.

"Mr. Hammer, I know what you said." Jing Xiaoran smiled, "But since you are worried so much, you are afraid that the new oral anticoagulant will not pass these clinical trials."

"Then after you Pfizer believe in my medicine, let's talk again."

What Hamer said is indeed correct. He is worthy of being the general manager of Pfizer's European and American regions. He is professional, logical, and even has strong lobbying skills.

But unfortunately, Jing Xiaoran's new oral anticoagulant is not a semi-finished product.

This drug has gone through all the clinical trials in the previous life, and even passed the tests of all patients after it was launched.

"Mr. Jing...you..." Hamer was at a loss for words.

"I'm very glad to meet Mr. Hammer today. Goodbye." Jing Xiaoran said with a smile, getting up and preparing to leave.

Hammer gritted his teeth, his hesitant expression became firm, and he stopped in front of Jing Xiaoran.

"Mr. Jing, please tell me about your conditions! I will help you meet what I can do!"

Jing Xiaoran stopped in his tracks, looked at Hamer with a pained face, and couldn't help but feel amused.

This person is really good at pretending, Jing Xiaoran believes that there is definitely a lot of room for maneuver in the conditions he gave, it can't just be seen on the surface.

"That's good." Jing Xiaoran sat down and said slowly, "First of all, I can accept the $1000 million buyout fee."

Hammer looked at Jing Xiaoran in surprise, he thought that Jing Xiaoran would take the opportunity to increase the buyout price several times.

"Mr. Jing, you continue."

"Secondly, I hope that new oral anticoagulant drugs will be launched simultaneously in Europe, America and China!"

Jing Xiaoran remembered that in his previous life, the new oral anticoagulant drug was launched in China five or six years after it was launched abroad, which was really not very friendly to domestic patients.

"That's no problem. Pfizer can carry out clinical trials of drugs in China and Europe and the United States at the same time." Hamer nodded, "If it goes well, we can guarantee that the two places will be launched at the same time."

"The last and most important point." Jing Xiaoran paused, "I need your help from Pfizer."

Hammer looked at Jing Xiaoran suspiciously.

He doesn't need to add money, and he doesn't settle in Pfizer, let alone come to the United States to study.

So what can Pfizer do for him?
(End of this chapter)